Kura Oncology : Corporate Presentation - May 2021

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

Corporate Presentation - May 2021

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib and KO-539, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and our expectations regarding the therapeutic and commercial potential of our product candidates. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investment Highlights

Targeted Oncology

Proprietary Pipeline

Advancing targeted oncology drug candidates using a precision medicine approach; fast-to-market strategy; global commercial rights

KO-539

• Novel menin inhibitor with potential to target 35% or more of AML
• Encouraging safety, tolerability and clinical activity in multiple genetically defined subgroups of AML
• Genetically enriched Phase 1 expansion cohorts expected to begin in mid-2021
  Tipifarnib

• Breakthrough Therapy* and Fast Track Designations from FDA

• Registration-directed trial in HRAS mutant HNSCC ongoing

• Opportunity to expand to HRAS and PI3Kα dependent tumors

Next-Generation Farnesyl Transferase Inhibitor

• Nomination of development candidate expected in mid-2021

Strong	$603.9 million in cash** provides runway into 2024
Financials

* For the treatment of patients with recurrent or metastatic HRAS mutant HNSCC with	3
variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy

** Cash, cash equivalents and short-term investments as of March 31, 2020

Kura Leadership Team and Board of Directors

Proven oncology drug development and commercialization expertise

Leadership Team	Board of Directors
Troy Wilson, Ph.D., J.D.	Faheem Hasnain
President & Chief Executive Officer	Chairman and Chief Executive Officer, Gossamer Bio
James Basta, J.D.	Robert Hoffman
Chief Legal Officer	Former Chief Financial Officer, Heron Therapeutics
Stephen Dale, M.D.	Thomas Malley
Chief Medical Officer	President, Mossrock Capital
Kirsten Flowers	Diane Parks
Chief Commercial Officer	Former Head of U.S. Commercial, Kite Pharma
Kathleen Ford	Steven Stein, M.D.
Chief Operating Officer	Chief Medical Officer, Incyte
Marc Grasso, M.D.	Mary Szela
Chief Financial Officer &	President and CEO, TriSalus Life Sciences
Chief Business Officer	Troy Wilson, Ph.D., J.D.
	President and CEO, Kura Oncology

4

Drug Candidate Pipeline

Program	Preclinical	Phase 1	Phase 2	Registration
Directed
KO-539	Acute Myeloid Leukemia (AML)
Menin Inhibitor	• Enrollment in Phase 1b expansion cohorts expected to begin in mid-2021
	HRASm Head & Neck Squamous Cell Carcinoma (HNSCC)
Tipifarnib	• Enrollment in AIM-HNregistration-directed trial ongoing
Farnesyl Transferase	PI3Kα / HRAS
Inhibitor
dependent HNSCC
	• Initiation of PI3Kα inhibitor combination study expected in 2H 2021
Next-Generation	Solid tumors
Farnesyl Transferase	• Nomination of development candidate expected in mid-2021
Inhibitor

5